- Home
- XGN vs CALC Comparison
XGN vs CALC Comparison
Compare XGN & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XGN
- CALC
- Stock Information
- Founded
- XGN 2002
- CALC 2011
- Country
- XGN United States
- CALC United States
- Employees
- XGN N/A
- CALC N/A
- Industry
- XGN Medical Specialities
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- XGN Health Care
- CALC Health Care
- Exchange
- XGN Nasdaq
- CALC Nasdaq
- Market Cap
- XGN 49.4M
- CALC 44.7M
- IPO Year
- XGN 2019
- CALC N/A
- Fundamental
- Price
- XGN $2.65
- CALC $3.90
- Analyst Decision
- XGN Buy
- CALC Strong Buy
- Analyst Count
- XGN 1
- CALC 4
- Target Price
- XGN $7.00
- CALC $20.50
- AVG Volume (30 Days)
- XGN 24.1K
- CALC 23.9K
- Earning Date
- XGN 11-11-2024
- CALC 11-07-2024
- Dividend Yield
- XGN N/A
- CALC N/A
- EPS Growth
- XGN N/A
- CALC N/A
- EPS
- XGN N/A
- CALC N/A
- Revenue
- XGN $56,660,000.00
- CALC N/A
- Revenue This Year
- XGN $9.98
- CALC N/A
- Revenue Next Year
- XGN $13.63
- CALC N/A
- P/E Ratio
- XGN N/A
- CALC N/A
- Revenue Growth
- XGN 7.05
- CALC N/A
- 52 Week Low
- XGN $1.30
- CALC $1.75
- 52 Week High
- XGN $3.71
- CALC $8.38
- Technical
- Relative Strength Index (RSI)
- XGN 39.30
- CALC 41.63
- Support Level
- XGN $2.64
- CALC $4.05
- Resistance Level
- XGN $3.03
- CALC $4.29
- Average True Range (ATR)
- XGN 0.17
- CALC 0.33
- MACD
- XGN -0.05
- CALC -0.05
- Stochastic Oscillator
- XGN 1.67
- CALC 10.17
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. Its proprietary technology targets the inhibition of calcium release-activated calcium channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are no approved therapies.